Plain-English translation of NCT02638142 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing furosemide, a common water-removal medication used in hospitals to treat acute heart failure. The study compares two ways of giving this medication intravenously: as a continuous drip versus as periodic injections. The goal is to figure out which method best relieves fluid buildup, protects kidney function, and improves outcomes for heart failure patients.
Doctors have long used this medication to help heart failure patients, but there's disagreement about the best way to deliver it. Most past research excluded patients with kidney problems, so doctors aren't sure whether continuous infusion or periodic doses work better—especially for protecting kidney health while relieving fluid buildup.
You likely qualify if…
You likely don't qualify if…
You will be admitted to the hospital and randomly assigned to receive the water-removal medication either as a steady, continuous drip or as periodic injections over the course of your hospitalization. Throughout your stay, doctors will monitor your kidney function, measure how well the fluid is being removed, and track your recovery. Blood tests and vital signs will be checked regularly to ensure the medication is working safely for you.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Italy
Sponsor
University of Siena
Collaborators
University of Roma La Sapienza, Ospedale Regina Montis Regalis
Enrollment target
~370 participants
Started
December 2015
Primary completion
January 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Alberto Palazzuoli, MD
University of Siena
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.